# US 2014/0155487 A1 · Method for correcting a lipid imbalance in a subject

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155487 A1
- Document ID: US20140155487A1
- Status: Published application
- Kind: A1
- Application number: 14/172,954
- Filed: 2014-02-05
- Published: 2014-06-05
- Earliest claimed: 2005-12-13
- Assignees: The Royal Institution for the Advancement of Learning/Mcgill University
- Applicants: The Royal Institution for the Advancement of Learning/Mcgill University
- Inventors: Danuta RADZIOCH; Claudine GUILBAULT; Juan Bautista DE SANCTIS
- Web page: https://patentgrep.com/patent/US20140155487A1

## CPC

- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods for the treatment of a disease or condition associated with lipid imbalance using fenretinide. The invention also relates to diagnostic and screening methods based on the determination of lipid levels.

## Claims

### Claim at position 1

1-39. (canceled)

### Claim 40

A method of treating a bone disease selected from osteoporosis and osteopenia in a subject having a lipid imbalance, said method comprising:
(i) selecting a subject having a lipid imbalance and suffering from said bone disease; and
(ii) (a) decreasing arachidonic acid (AA) levels, (b) increasing docosahexaenoic acid (DHA) levels, c) increasing the DHA/AA ratio, or (d) any combination of (a)-(c), by administering to said subject an effective amount of fenretinide or a pharmaceutically-acceptable salt thereof.

### Claim 41 (depends on 40)

The method of claim 40, wherein said increase of DHA levels or of the DHA/AA ratio or said decrease of AA levels is systemic.

### Claim 42 (depends on 40)

The method of claim 40, wherein said subject suffers from cystic fibrosis.

### Claim 43 (depends on 40)

The method according to claim 40, wherein said subject has (a) a DHA/AA ratio of 0.4 or less, (b) DHA levels of 3.5 ng/μg of phosphate or less, (c) AA levels of 40 ng/μg of phosphate or more or (d) any combination of (a) to (c), prior to said administration.

### Claim 44 (depends on 40)

The method of claim 40, wherein said DHA and AA are phospholipid-associated fractions of DHA and AA.

### Claim 45 (depends on 40)

The method of claim 40, wherein said subject is a mammal.

### Claim 46 (depends on 45)

The method of claim 45, wherein said mammal is a human.

### Claim 47 (depends on 40)

The method of claim 40, wherein said method comprises administering to said subject an effective amount of fenretinide.

### Claim 48 (depends on 40)

The method of claim 40, wherein said bone disease is osteoporosis.

### Claim 49 (depends on 40)

The method of claim 40, wherein said bone disease is osteopenia.

### Claim 50 (depends on 47)

The method of claim 47, wherein said bone disease is osteoporosis.

### Claim 51 (depends on 47)

The method of claim 47, wherein said bone disease is osteopenia.